Skip to main content

Table 1 Demographic and disease characteristics

From: Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma

Characteristics/Variable No. of patients (%)
Age
 Median 61.5
 Range 49–81
Sex
 Female 2 (16.7)
 Male 10 (83.3)
ECOG (screening)
 Grade 0 10 (83.3)
 Grade 1 2 (16.7)
Time from diagnosis to treatment 1.0 month (Mdn)
Metastatic disease 11 (91.7)
Histologic subtypes
 Clear cell 11 (91.6)
 Non-clear cell (papillary) 1 (8.4)
 Sarcomatoid features 6 (50)
Fuhrman nuclear grade
 Grade 1 2 (16.7)
 Grade 3 7 (58.3)
 Grade 4 3 (25.0)
MSKCC [38] and/or IMDC [39] variables
  < 1 year from diagnosis to targeted treatment 11 (100)
 Karnofsky performance status <80% 1 (9.1)
 Haemoglobin < LLN 8 (72.7)
 Serum corrected calcium conc. > ULN 5 (45.5)
 Lactate dehydrogenase >1.5 x ULN 1 (9.1)
 Neutrophil count > ULN 0 (0)
 Paltelet count > ULN 3 (27.2)
MSKCC prognostic group
 Favourable 0 (0)
 Intermediate 5 (45.5)
 Poor 6 (54.5)
IMDC prognostic group
 Favourable 0 (0)
 Intermediate 6 (54.5)
 Poor 5 (45.5)
  1. Abbreviations: LLN lower limit of normal, ULN upper limit of normal, MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic RCC Database, Mdn median